PDCD1 and non-small cell lung carcinoma: There was one, seven, fifteen, and three of 27 NSCLC patients achieved CR, PR, SD, and PD, respectively, with ORR 30% and mPFS 9.7 months, which was a favorable result compared with anti-PD-1/PD-L1 antibody treatment alone in other studies (44).